New drugs and new approaches in metastatic bladder cancer

Critical Reviews in Oncology/Hematology

Volumn 47, Issue 2, 2003, Pages 195-206

  Bellmunt, J ^a   De Wit, R ^b   Albiol, S ^a   Tabernero, J ^a   Albanell, J ^a   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Bladder cancer; Chemotherapy; Cisplatin; Gemcitabine; New agents; Paclitaxel; Urothelial cell cancer

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EKI 569; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LOBAPLATIN; LONAFARNIB; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; OXALIPLATIN; PACLITAXEL; PD 166285; PIRITREXIM; SEMAXANIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VINBLASTINE;

ALOPECIA; ANEMIA; ANGIOGENESIS; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0043169600     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00082-9     Document Type: Review

References (111)

1. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133:1985;403-407.
2. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapsed. Cancer. 64:1989;2448-2458.
3. Harker W.G., Meyers F.J., Freiha F.S., et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract; a Northern California Oncology Group Study. J. Clin. Oncol. 3:1985;1463-1470.
4. Roth B.J., Bajorin D. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J. Urol. 153:1995;894-900.
5. Sher H.I., Shipley W.U., Herr H.W. Cancer of the bladder. De Vita V.T. Jr., Hellman S., Rosenberg S.A. Cancer: principles and practice of oncology. 1997;1300-1322 Lippincott-Raven Publishers, Philadelphia, PA.
6. Sternberg C.N., Yagoda A., Scher H.I., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 139:1988;461-469.
7. Boutan-Larozc A., Mabjoubi M., Droz J.P., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur. J. Cancer. 27:1991;1690-1694.
8. Loerhrer P.J., Einhorm L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorrubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10:1992;1066-1073.
9. Troner M., Birch R., Omura G.A., et al. Phase III comparison of cisplatin alone versus cisplatin, doxorrubicin, and cyclophosphamide in the treatment of bladder cancer: a Southeastern Cancer Study Group Trial. J. Urol. 137:1987;660-662.
10. Fossa S.D., Sternberg C.N., Scher H.I., et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br. J. Cancer. 74:1996;1492-1498.
11. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8:1990;1050-1055.
12. Bellmunt J., Ribas A., Eres N., et al. Carboplatin based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 80:1997;1966-1972.
13. Mead G.M., Crook A.M., Russell J.M. An MRC randomized trial comparing MV (methotrexate and vinblastine) with CMV (cisplatin+MV) for metastatic transitional cell cancer (TCC). Proc. Am. Soc. Clin. Oncol. 15:1996;241.
14. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 15:1997;2564-2569.
15. Von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 17:2000;3068-3077.
16. Geller N.L., Sternberg C.N., Penenberg D., et al. Prognostic factor for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 67:1991;1525-1531.
17. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17:1999;3173-3181.
18. Waxman J., Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat. Rev. 19:(Suppl C):1993;21-25.
19. Sternberg C.N., De Mulder P., Sternberg C.N., et al. Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Ann. Oncol. 8:1997;695-696.
20. Witte R.S., Elson P., Bono B., et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinomam. J. Clin. Oncol. 15:1997;589-593.
21. Witte R.S., Elson P., Khandaker J., et al. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in treatment of advanced urothelial carcinoma. Cancer. 73:1994;688-691.
22. de Wit R., Kayne S.B., Robert J.T., et al. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br. J. Cancer. 67:1993;388-390.
23. Khorsand M., Lange J., Feun L., et al. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest. New Drugs. 15:1997;157-163.
24. Paz-Ares L., Tabernero J., Moyano A., et al. A phase II of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma of the bladder. Proc. Am. Soc. Clin. Oncol. 17:1998;A1307.
25. Roth B., Dreicer R., Einhorn L.H., et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the ECOG. J. Clin. Oncol. 12:1994;2264-2270.
26. Dreicer R., Gustin D.M., See W.A., et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J. Urol. 156:1996;1606-1608.
27. McCaffery J.A., Hilton S., Mazumdar S. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 15:1997;1853-1857.
28. de Wit R., Kruit W.H., Stoter G., et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br. J. Cancer. 78:1998;1342-1345.
29. Pollera C.F., Ceribelli A., Grecco M., et al. Weekly gemcitabine in advanced bladder cancer. A preliminary report from a phase I study. Ann. Oncol. 5:1994;182-184.
30. Lorusso V., Pollera C.F., Antimi M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian co-operative group on bladder cancer. Eur. J. Cancer. 34:1998;1208-1212.
31. Gebbia V., Testa A., Borsellino N., et al. Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin. Ter. 150:1999;11-15.
32. Stadler W.M., Kuzel T., Roth B., et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 15:1997;3394-3398.
33. Moore M.J., Tannock I., Ernst S., et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol. 15:1997;3441-3445.
34. Fuchs D.A., Johnson R.K. Cytologic evidence that Taxol, an antineoplastic agent from Taxus Brevifolia, acts as a mitotic spindle poison. Cancer Treat. Rep. 62:1978;1219-1222.
35. Niell H.B., Rangel C., Miller A., et al. The activity of antimicrotubular agents in human bladder tumor cell lines (HBTCL). Proc. Am. Assoc. Cancer Res. 34:1993;A202.
36. Rangel C., Niell H., Miller A., et al. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chem. Phar. 33:1994;460-464.
37. Murphy B.A., Johnson D.R., Smith J., et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc. Am. Soc. Clin. Oncol. 15:1996;A245.
38. Dreicer R., Manola J., Roth B.J., et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 18:2000;1058-1061.
39. Burch P.A., Richardson R.L., Cha S.S., et al. Phase II study of paclitaxel and cisplatin in advanced urothelial carcinoma. J. Urol. 164:2000;1538-1542.
40. Sengelov L., Kamby C., Lund B., et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J. Clin. Oncol. 16:1998;3392-3397.
41. Dimopoulos M.A., Bakoyannis C., Georgoulias V., et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter fase II study of the Hellenic Cooperative Oncology Group. Ann. Oncol. 10:1999;1385-1388.
42. García del Muro X., Marcuello E., Guma J., et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br. J. Cancer. 86:2002;326-330.
43. Zielinsky C.C., Schnack B., Grbovic M., et al. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br. J. Cancer. 78:1998;370-374.
44. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 16:1998;255-260.
45. Redman B.G., Smith D.C., Flaherty L., et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J. Clin. Oncol. 16:1998;1844-1848.
46. Pycha A., Grbovic M., Posch B., et al. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology. 53:1999;510-515.
47. Small E.J., Lew D., Redman B.G., et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J. Clin. Oncol. 18:2000;2537-2544.
48. Droz J.P., Mottet N., Prapotich D., et al. Phase II study of Taxol (paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium: preliminary results. Proc. Am. Soc. Clin. Oncol. 17:1998;A316.
49. Bauer J., Stalder M., Roth A., et al. Phase II trial of paclitaxel (P) plus carboplatin (C) in advanced urothelial tract cancer (UTC). Proc. Am. Soc. Clin. Oncol. 17:1998;A326.
50. Vaughn D.J., Dreicer R., Manola J., et al. E2896 paclitaxel/carboplatin in advanced urothelial carcinoma and renal insufficiency: a phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc. Am. Soc. Clin. Oncol. 19:2000;A343.
51. Friedland D.M., Berry W.B., Senzer N., et al. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;A352.
52. Bellmunt J., Albanell J., Gallego O., et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 70:1992;1974-1979.
53. Petriolli R., Frediani B., Manganelli A., et al. Comparison between a cisplatin-containing regimen for recurrent or metastatic bladder cancer patients. Cancer. 77:1996;344-351.
54. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Sem. Oncol. 22:1995;72-79.
55. Von der Maase H., Andersen L., Crino L., et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann. Oncol. 10:1999;1641-1645.
56. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18:2000;1921-1927.
57. Moore M.J., Winquist E., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17:1999;2876-2880.
58. Bellmunt J., Wit de R., Albanell J., Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur. J. Cancer. 37:2001;2212-2221.
59. Bellmunt J., Guillem V., Paz-Ares J.L., et al. A phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J. Clin. Oncol. 18:2000;3247-3255.
60. Frassoldati A., Bisagni G., Passalacqua R., et al. Gemcitabine, cisplatin and paclitaxel in advanced transitional bladder cancer. Is there a schedule-dependent clinical effect? Proc. Am. Soc. Clin. Oncol. 19:2000;A366.
61. Hussain M., Vaishampayan U., Du W., et al. Combination carboplatin, paclitaxel and gemcitabine. Is an active treatment for advanced urothelial carcinoma. J. Clin. Oncol. 19:2001;2527-2533.
62. Hovey E.J., Owen C.E., Shelton E.B., et al. Phase I/II study of docetaxel, gemcitabine, carboplatin in poor prognosis and previously treated patients with urothelial carcinoma. Proc. Am. Soc. Clin. Oncol. 19:2000;A350.
63. Bajorin D.F., McCaffrey J.A., Hilton S., et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: a phase II trial. J. Clin. Oncol. 16:1998;2722-2727.
64. Bajorin D.F., McCaffrey J.A., Dodd P.M., et al. Ifosfamide, paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer. 88:2000;1671-1678.
65. Tu S.M., Hossan E., Amato R., et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J. Urol. 154:1995;1719-1722.
66. Edelman M.J., Meyers F.J., Miller T.R., et al. Phase I/II study of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma: a well tolerated regimen with activity independent of p53 mutation. Urology. 55:2000;521-525.
67. Pectasides D., Visvikis A., Aspropotamitis A., et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Eur. J. Cancer. 36:2000;74-79.
68. Petrylak D.P., Scher H.I., Reuter V., et al. P-Glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann. Oncol. 5:1994;835-840.
69. Pendyala L., Velagapudi S., Toth K., et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin. Cancer Res. 13:1997;793-798.
70. Siu L.L., Banerjee D., Khurana R.J., et al. The prognostic role of p53, metallothionein, P-glycoprotein and MIB-1 in muscle invasive urothelial transitional cell carcinoma. Clin. Cancer Res. 4:1998;559-565.
71. Esring D., Elmaijian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331:1994;1259-1264.
72. Cordon-Cardo C., Zhang Z.-F., Dalbagni G., et al. Cooperative effects of p53 and pRb alterations in primary superficial bladder tumors. Cancer Res. 57:1997;1217-1221.
73. Zhang Z.-T., Pak J., Huang H.-Y., et al. Role of H-Ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 20:2001;1973-1980.
74. Sarkis A., Bajorin D., Reuter V., et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol. 13:1996;1384-1390.
75. Edelman M.J., Meyers F.J., Miller T.R., et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology. 55:2000;521-525.
76. Duggan B., Kelly J., Keane P.F., et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int. 86:2000;757.
77. Van Brussel J.P., Mickisch G.H. Circumvention of multidrug resistance in genitourinary tumors. Int. J. Urol. 5:1998;1-15.
78. Seidman A.D., Scher H.I., Gabrilove J.L., et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J. Clin. Oncol. 11:1993;408-414.
79. Loehrer P.J., Elson P., Dreicer R., et al. Escalated dosages of methotrexate, vinblastine doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 12:1994;483-488.
80. Logothetis C.J., Finn L.D., Smith T., et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J. Clin. Oncol. 13:1995;2272-2277.
81. Sternberg C.N., de Mulder P.H., Schornagel J., et al. Randomized phase III trial in advanced urothelial tract tumors of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC. J. Clin. Oncol. 19:2001;2638-2646.
82. Dodd P.M., McCaffrey J.A., Hilton S., et al. Phase I evaluation of sequential doxorubicin+gemcitabine then ifosfamide+paclitaxel+cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J. Clin. Oncol. 18:2000;840-846.
83. Maluf F.C., Hilton S., Nanus M., et al. Sequential doxorubicin/gemcitabine and ifosfamide, paclitaxel and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Proc. Am. Soc. Clin. Oncol. 19:2000;A342.
84. Novick S., Higgins G., Hilton S., et al. Phase I/II sequential doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with transitional cell carcinoma and impaired renal function. Proc. Am. Soc. Clin. Oncol. 19:2000;A361.
85. Isla D., Rosell R., Sanchez J.J., et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 19:2001;1071-1077.
86. Sternberg C.N., Calabro F., Pizzocaro G., et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 92:2001;2993-2998.
87. Meluch A.A., Greco F.A., Burris H.A., et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 19:2001;3018-3024.
88. Kaufman D.S., Stadler W.M., Carducci M.A., et al. Gemcitabine and paclitaxel every two weeks: a multicenter phase II trial in locally advanced or metastatic urothelial cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;A341.
89. Parameswaran R., Fisch M.J., Ansari R.H., et al. A hoosier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell carcinoma of the bladder. Proc. Am. Soc. Clin. Oncol. 20:2001;A200.
90. Law L.Y., Lara P.N., Meyers F.J., et al. Platinum free combination chemotherapy in locally advanced and metastatic transitional cell carcinoma: phase I/II trial of gemcitabine, paclitaxel, methotrexate. Proc. Am. Soc. Clin. Oncol. 20:2001;A192.
91. Lipponen P., Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer. 69:1994;1120-1125.
92. Korkolopoulou P., Christodoulou P., Kapralos P., et al. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol. Res. Pract. 193:1997;767-775.
93. Chow N.H., Chan S.H., Tzai T.S., et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7:2001;1957-1962.
94. Neal D.E., Marsh C., Bennett M.K., et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1:1985;366-369.
95. Izawa J.I., Slaton J.W., Kedar D., et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol. Rep. 8:2001;9-15.
96. Ravery V., Grignon D., Angulo J., et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol. Res. 25:1997;9-17.
97. Rubin M.S., Shin D.M., Pasmatier M., et al. Monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor, for patients with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc. Am. Soc. Clin. Oncol. 19:2000;A474.
98. Ferry D., Hommond L., Ronson M., et al. Intermittent oral ZD 1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor, shows evidence of good tolerability and activity: finals results from a phase I study. Proc. Am. Soc. Clin. Oncol. 19:2000;A3.
99. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of theEGF receptor inhibitorZD1839 ('Iressa') in skin from cancer patients: histopathological and molecular consequences of receptor inhibition. J. Clin. Oncol. 20:2002;110-124.
100. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:2000;4885-4892.
101. Miller V.A., Johnson D., Heelan R.T., et al. A pilot trial demonstrates the safety of ZD1839 (Iressa) an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;A326.
102. Weiner L.M. An overview of monoclonal antibody therapy of cancer. Sem. Oncol. 26:(Suppl 12):1999;71-77.
103. Inoue K., Slaton J.W., Perrotte P., et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6:2000;4874-4884.
104. Jimenez R.E., Hussain M., Bianco F.J. Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7:2001;2440-2447.
105. Estrada C.R., Coogan C.L., Kapur S., et al. Her-2/neu receptor protein over-expression in grade I, II and III bladder transitional cell carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;A199.
106. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
107. Shao Z.M., Nguyen M. Angiogenic factors and bladder cancer. Front. Biosci. 7:2002;33-35.
108. Inoue K., Slaton J.W., Davis D.W., et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res. 6:2000;2636-2643.
109. Inoue K., Perrotte P., Wood C.G., et al. Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin. Cancer Res. 6:2000;4422-4431.
110. Inoue K., Slaton J.W., Karashima T., et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res. 6:2000;4866-4873.
111. Winquist E., Moore M.J., Chi K., et al. NCIC CTG IND.128: a phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol. 20:2001;A197.